advertisement

Topcon

Ward CL 9

Showing records 1 to 9 | Display all abstracts from Ward CL

69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Harris A
Journal of Glaucoma 2016; 25: e826-e833
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Miller Ellis E; Berlin MS
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Ward CL; Rowe-Rendleman CL
Journal of Glaucoma 2016; 25: e826-e833
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Ward CL
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Ouchi T
Journal of Glaucoma 2016; 25: e826-e833
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Sharpe JA
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Wood A
Journal of Glaucoma 2016; 25: e826-e833
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Jamil A; Harris A
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Fujii A; Serle JB
Journal of Glaucoma 2016; 25: e826-e833

Issue 18-2

Change Issue


advertisement

Topcon